(Alliance News) - DiaSorin Spa announced Thursday that it has received 510k clearance from the U.S. Food and Drug Administration for the NxTAG Respiratory Pathogen Panel v2.

This updated panel adds to Diasorin's expanding molecular multiplexing portfolio, enhancing the usability of the test, the company notes in a note.

DiaSorin collaborated with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development and obtain clearance of this syndromic panel.

This project was funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority.

DiaSorin's stock closed Wednesday in the green by 0.4 percent at EUR101.55 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.